Compugen Ltd. Stock price

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.54 USD +1.60% Intraday chart for Compugen Ltd. -5.58% +28.28%
Sales 2024 * 37.9M Sales 2025 * 35.29M Capitalization 227M
Net income 2024 * -13M Net income 2025 * -29M EV / Sales 2024 * 6 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 6.44 x
P/E ratio 2024 *
-19.5 x
P/E ratio 2025 *
-9.41 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.60%
1 week-5.58%
Current month-1.55%
1 month-4.15%
3 months+43.50%
6 months+173.12%
Current year+28.28%
More quotes
1 week
2.44
Extreme 2.44
2.67
1 month
2.34
Extreme 2.34
3.03
Current year
1.72
Extreme 1.72
3.03
1 year
0.53
Extreme 0.53
3.03
3 years
0.51
Extreme 0.51
9.30
5 years
0.51
Extreme 0.51
19.90
10 years
0.51
Extreme 0.51
19.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 01-12-31
Director of Finance/CFO 61 22-10-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 65 17-10-01
Director/Board Member 68 18-06-10
Director/Board Member 57 18-06-10
More insiders
Date Price Change Volume
24-03-27 2.54 +1.60% 312,741
24-03-26 2.5 -1.19% 215,475
24-03-25 2.53 -4.17% 294,933
24-03-22 2.64 -1.12% 232,606
24-03-21 2.67 -0.74% 237,306

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.54 USD
Average target price
5.333 USD
Spread / Average Target
+109.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Compugen Ltd. - Nasdaq